Sichuan Biokin Pharmaceutical (SHA:688506) completed the enrollment of its first subject in the Phase III clinical trial on BL-M05D1 injection, according to a Shanghai bourse filing on Friday.
The drug is being tested as a treatment for patients with Claudin18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma who have previously received first-line therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.